News | October 06, 2024
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The acquisition will strengthen the overall company’s position as leading global CRO services partner
This is used to treat central diabetes insipidus and bedwetting
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
The company will also share results in two additional posters for deuruxolitinib
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Subscribe To Our Newsletter & Stay Updated
